Alignment Healthcare (ALHC) Q1 2026 earnings review
Inflection Point: Hyper-Growth Meets GAAP Profitability
Alignment Healthcare delivered a massive beat-and-raise in 26Q1, proving that its care-centric model can thrive while legacy Medicare Advantage players struggle. The company achieved 33.3% YoY revenue growth while simultaneously reversing its bottom line from a $9.4M net loss a year ago to a $11.4M GAAP net income. Management's ability to drive membership up by nearly 31% to ~284,800 while actually improving the Medical Benefits Ratio (MBR) by 25 basis points to 88.2% validates their proprietary AVA technology platform. As a result, guidance was raised across the board, setting up 2026 as a breakout year for scaled profitability.
🐂 Bull Case
ALHC is disproving the industry thesis that rapid Medicare Advantage growth ruins margins. By strictly controlling inpatient admissions via its AVA platform, MBR improved despite absorbing a massive cohort of new members.
With high Star ratings (100% of members in 4+ star plans) and competitors cutting benefits due to V28 risk model pressures, ALHC is successfully capturing displaced market share at an accelerating rate.
🐻 Bear Case
The macro environment for MA remains hostile. A flat initial 2027 CMS rate notice implies that future growth will rely entirely on internal cost management rather than rising government reimbursement.
New members, heavily skewed toward dual-eligible and C-SNP populations, traditionally carry a higher MBR in their first year. If clinical onboarding stumbles, it could aggressively compress second-half margins.
⚖️ Verdict: 🟢
Highly Bullish. Delivering 30%+ top-line growth while structurally expanding margins and flipping to GAAP profitability is rare in the current Medicare Advantage landscape. ALHC is effectively weaponizing its technology to exploit competitor weakness.
Key Themes
AVA Platform Defends the MBR
The core thesis for ALHC is its ability to manage medical costs better than global capitation models. In 26Q1, the Medical Benefits Ratio (MBR) improved by 25 basis points to 88.2%. This is a critical metric: it shows that their clinical visibility and control mechanisms (resulting in low inpatient admission rates) are successfully absorbing the initial utilization shock of a 30.9% larger member base.
Operating Leverage is Accelerating
SG&A as a percentage of revenue is shrinking as the business scales. Total SG&A was $121.1M in 26Q1. Stripping out $12.6M in equity-based compensation, adjusted SG&A was roughly 8.7% of total revenue. This represents significant efficiency gains over historical periods, driven by investments in workflow automation and AI administrative tools that allow the back office to support 284,800 members without a linear increase in headcount.
Thriving in a Punishing MA Environment
The broader Medicare Advantage industry is buckling under the phase-in of the V28 risk model and Part D redesigns. ALHC views this dislocation as an acquisition event. Because their blended Risk Adjustment Factor (RAF) score was already conservative (below 1.1), they face less downward revision pressure than peers historically operating at 1.5+. This allows them to maintain stable benefits and poach 'plan switchers'.
New Member Mix Pressures H2 Margins
A substantial portion of the newly acquired members are LIS (Low-Income Subsidy), dual-eligible, or C-SNP. These demographics traditionally run 'hotter' in their first year. While the Q1 MBR looks strong, management has historically cautioned that the slope of Part D and complex care costs flattens out, meaning MBR could tick upward in subsequent quarters as these cohorts utilize their benefits.
2027 Rate Uncertainty
While ALHC is executing flawlessly today, it operates in a heavily regulated market. CMS is signaling a flat rate environment for 2027, alongside crackdowns on chart reviews. Although ALHC has minimal exposure to unlinked chart reviews (approx. 1% of HCC value), stagnant baseline funding requires them to perpetually manufacture 4-5% operational efficiencies simply to offset medical inflation.
Other KPIs
Accelerating dramatically. Operating cash flow surged from $16.6M in 25Q1 to $128.7M in 26Q1. This was largely driven by a $181.4M increase in medical expenses payable, reflecting the massive influx of new members and the timing of claims payments. This liquidity generation fully funds their geographic expansion without the need to tap their $200M credit facility.
Stable and strengthening. Cash balances grew by $129.8M sequentially from Q4 2025. This fortress balance sheet insulates the company from high interest rates and gives them the firepower to execute tuck-in acquisitions of specialty captives (e.g., dental or behavioral networks) to internally capture supplemental benefit spending.
Guidance
Stable sequential growth expected. At the midpoint (289,000), this represents a ~29% YoY increase compared to 25Q2 (223,700). The slight deceleration in the YoY percentage (down from 30.9% in Q1) is a natural function of the law of large numbers and the end of the primary Open Enrollment Period.
Accelerating total scale. The midpoint of $5.18B represents a massive increase over FY25. This raise reflects both higher-than-expected member retention and strong gross adds from AEP plan switchers.
Accelerating dramatically. The midpoint ($150.5M) signifies explosive operating leverage when compared to the ~$110M generated in FY25. This proves that gross profit dollars from new members are falling straight to the bottom line.
Accelerating. The midpoint of $172M implies an expanding gross margin relative to Q1 ($145.9M). This suggests management anticipates further medical cost normalization and potential realization of risk adjustment sweeps.
Key Questions
Dual-Eligible Integration and MBR Impact
With 50% of recent AEP growth coming from LIS, duals, and C-SNP members, what specific clinical interventions are you running through AVA in Q2 to ensure these historically high-MBR populations don't compress margins in the second half of the year?
Capital Deployment Strategy
With operating cash flow hitting nearly $129M for the quarter and total cash cresting $705M, what is the trigger point for actively acquiring specialty captives to capture the 4-5% of premium currently spent on supplemental benefits?
Ex-California Provider Engagement
Given your comments last quarter about needing to 'get better' at provider engagement outside of California, how has the utilization of the Care Anywhere platform trended in newly expanded markets like Texas and Nevada over the last 90 days?